TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01993134

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Cefazolin, 2g/IV, prior to surgery, and after surgery recieved 4 aditional doses 1g/IV of Cefazolin.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin Single Dose
Description: Patients received 2g of Cefazolin (Cefazolin Sodium - Ampoule- 1g - Genéricos Brasil), administered intravenously but none was administered in the post-operative period
Study: NCT00115193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: pegfilgrastim 6 mg on day 1 of each cycle (within 4 hours of chemotherapy completion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: pegfilgrastim 6 mg on day 2 of each cycle (at least 24 hours after chemotherapy completion)
Study: NCT00860626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon α plus nucleoside analogue
Description: Standard dose of interferon is used for 12 weeks. On 12th week of treatment, HBV DNA is still detectable (\>1000 copies/ml), or HBeAg is still positive. And lamivudine is added for 3 months. After nucleoside analogue is added for 3 months, HBV DNA is tested again. If negative, stop nucleoside analogue and use interferon alone for another 6 months or longer. If HBV DNA is still positive, change to another nucleoside analogue or add another nucleoside analogue.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon α
Description: Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is still detectable (\>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon α
Description: Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is undetectable, or HBeAg is negative. And interferon is continued alone for another 9 months.
Study: NCT00006695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: 300 mg/m2 IV on Day -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 100 mg/m2 BID on Days -5 through -2
Study: NCT01938001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375mg/m\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 20mg by mouth (PO) daily on Days 1 to 21 every 28 days up to 12 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (identical matched capsule) PO daily on Days 1 to 21 every 28 days
Study: NCT00990249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Test Dose 32 mg/m\^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 40 mg/m\^2 by vein over 1 hour daily Day -6 through Day -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell infusion on Day 0.
Study: NCT01213498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Zarator, 80 mg pr. day for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Unikalk
Description: 1 tablet Unikalk pr day for 5. days
Study: NCT01078519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined epidural and spinal anesthesia
Description: Obstetrics patients will relieve spinal anesthesia with local anesthesics and opioids associated with epidural anesthesia with local anesthetics in low concentrations with opioids
Study: NCT00751179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium
Description: A single bolus intubation dose of 0.6 mg/kg rocuronium will be administered following induction of anesthesia and if required, single bolus dose(s) of 0.15 mg/kg rocuronium will be administered to maintain the neuromuscular block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: At the end of the surgical procedure at a target depth of neuromuscular blockade of at least 1-2 Post-Tetanic Count (PTC), 4.0 mg/kg of sugammadex will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: succinylcholine
Description: A single bolus intubation dose of 1.0 mg/kg succinylcholine will be administered following induction of anesthesia and the subject is allowed to recover spontaneously from the neuromuscular blockade.
Study: NCT03104036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faecal bacterial transplantation
Description: Enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine 4G Enema
Description: Standard mesalazine enema
Study: NCT00313248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (ZK 219477)
Description: All patients will receive ZK-Epo at a dose of 16mg/m2 as an intravenous infusion. Chemotherapy for recurrent breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (ZK 219477)
Description: Patients will receive 22mg/m2 as intravenous infusion.
Study: NCT03363919

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroStar TMS Therapy® System
Description: The NeuroStar TMS Therapy® System is a computerized electromechanical instrument that produces and delivers brief duration, rapidly alternating (pulsed) magnetic fields to induce electrical currents in localized regions of the cerebral cortex. It is a non-invasive tool used for the treatment of Participants with Major Depressive Disorder (MDD) who have not achieved sufficient clinical benefit from antidepressant pharmacotherapy.
Study: NCT01367405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical decompression
Description: Surgical decompression within 24 hour postinjury
Study: NCT03889366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant 125 mg
Description: Single dose in the fasted state during treatment period 1,2 or 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Description: Single dose in the fasted state during treatment period 1,2 or 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Description: Single dose in the fasted state during treatment period 1,2 or 3
Study: NCT03363919

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroStar TMS Therapy® System
Description: The NeuroStar TMS Therapy® System is a computerized electromechanical instrument that produces and delivers brief duration, rapidly alternating (pulsed) magnetic fields to induce electrical currents in localized regions of the cerebral cortex. It is a non-invasive tool used for the treatment of Participants with Major Depressive Disorder (MDD) who have not achieved sufficient clinical benefit from antidepressant pharmacotherapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroStar XPLOR®
Description: NeuroStar XPLOR® is a clinical research option for the NeuroStar TMS Therapy System that provides features necessary to conduct randomized controlled trials and other TMS research.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroStar XPLOR®
Description: NeuroStar XPLOR® is a clinical research option for the NeuroStar TMS Therapy System that provides features necessary to conduct randomized controlled trials and other TMS research.
Study: NCT04384744

Intervention type: DRUG
Intervention: growth hormone
Description: growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.
Study: NCT00415766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rHCG 250ug
Description: Injection of 250 ug Ovitrelle to trigger final oocyte maturation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: uHCG 5000 IU
Description: Injection of 5000 IU Pregnyl to trigger final oocyte maturation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: uHCG 7500 IU
Description: Injection of 7500 IU Pregnyl to trigger final oocyte maturation
Study: NCT00523224

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angiogenic Cell Precursors(ACPs) or Vescell TM
Description: at least 1.5 million of ACPs per one time of treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Angiogenic Cell Precusors
Description: Stem cells type Angiogenic Cell Precusors(ACPs) at least 1.5 million ACPs per each treatment
Study: NCT04199013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.75% Injectable Solution
Description: Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.75% Injectable Solution
Description: Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
Study: NCT02998970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: single oral tablet once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral tablet once daily.
Study: NCT03161964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol 80 Mg Oral Capsule, Extended Release
Description: Propranolol capsule over-encapsulated to match placebo for blinding
Study: NCT00006695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 100 mg/m2 BID on Days -5 through -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 140 mg/m2 IV on Day -1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Following the chemotherapy, on Day 0 of treatment, the previously stored hematopoietic stem cells will be administered to the patient intravenously through a central line to the patient.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tositumomab and iodine I 131 tositumomab
Description: Patients will receive two administrations of Iodine-131 Anti-B1 Antibody; the dosimetric dose and the therapeutic dose. The dosimetric dose will consist of an infusion of unlabeled Anti-B1 Antibody (450 mg) immediately followed by an infusion of Anti-B1 Antibody (35 mg) which has been trace labeled with 5 mCi of Iodine-131 Anti-B1 Antibody. Using whole body anterior and posterior gamma camera scans and serial imaging studies over approximately one week, the clearance of the whole body dosimetric dose will be used to calculate the subsequent therapeutic dose of Iodine-131 Anti-B1 Antibody which delivers a total body dose of 75 cGy to the subject
Study: NCT00480740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization
Study: NCT02382991

Intervention type: DEVICE
Group type: OTHER
Intervention: 3C60-NMPK
Description: 3 months with 3C60 - 10 days wash out - 1 month with NMPK
Study: NCT01758432

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Apixaban

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Apixaban
Study: NCT01367405

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Usual conservative treatment without surgery
Study: NCT02814838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ladarixin
Description: Ladarixin oral capsule
Study: NCT00648570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram Oxalate Tablets 20 mg
Description: 20mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lexapro® Tablets (20 mg
Description: 20mg, single dose fasting
Study: NCT04226287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monterey Pneumatic Compression Device
Description: The MontereyInvestigational System is a compact pneumatic compression device used for the treatment of either primary or secondary lymphedema. The primary intention in this study is to gather usability design feedback. This will be done by observing how a patient uses the device after a brief demonstration from the clinician. Errors and difficulties will be noted by the ResMed representative observing the trial. The qualitative interview with the patient at the end of the trial will yield additional understanding of the patient experience with the device.
Study: NCT02884518

Intervention type: DEVICE
Group type: OTHER
Intervention: PET
Description: Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they and healthy controls will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity of presynaptic dopamine and relapse in the patients discontinuing treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET
Description: Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they and healthy controls will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity of presynaptic dopamine and relapse in the patients discontinuing treatment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: clinical scale
Description: Healthy controls should complete clinical scales at baseline. Patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: clinical scale
Description: Healthy controls should complete clinical scales at baseline. Patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
Study: NCT00989404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: Rotahaler placebo 10mg BID 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: Rotahaler Zanamivir 10mg BID 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: Diskhaler Zanamivir 10mg BID 5 days
Study: NCT02687932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Study: NCT00561613

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SILCS and lubricant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SILCS and spermicide
Study: NCT02627833

Intervention type: OTHER
Intervention: observation
Description: Record lung function, Lung clearance index, inflammatory status

Intervention type: OTHER
Intervention: observation
Description: Record lung function, Lung clearance index, inflammatory status
Study: NCT03682939

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero® (meningitis B vaccine)
Description: Bexsero® 0.5ml IM vaccine administered into non-dominant arm of participant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menveo® (meningitis ACWY vaccine)
Description: Menveo® 0.5ml IM vaccine administered into dominant arm of participant
Study: NCT03161964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo capsule over-encapsulated to match propranolol for blinding
Study: NCT01921530

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interbody Fusion
Description: The interbody fusion (IF) procedure requires exposure and removal of the disc, curetting the end plates, inserting a cage filled with bone graft, as well as stabilization with rods and screws.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterolateral Fusion
Description: In posterolateral fusion stabilization is achieved using pedicle screws joined by rods. The graft used to facilitate fusion is placed between decorticated transverse processes and can be an autograft of iliac bone or local bone, allograft, or a synthetic expander.
Study: NCT03984123

Intervention type: DEVICE
Group type: OTHER
Intervention: Brachial cuff, in order to achieve ischemic stimuli
Description: Standard treatment with no brachial cuff inflation

Intervention type: DEVICE
Group type: OTHER
Intervention: Brachial cuff, in order to achieve ischemic stimuli
Description: Standard treatment with no brachial cuff inflation
Study: NCT02242565

Intervention type: DEVICE
Group type: OTHER
Intervention: ShangRing
Description: ShangRing device for male circumcision

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ShangRing
Description: ShangRing device for male circumcision
Study: NCT02261844

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol 1 gm po x 10 days prior to liver resection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 pill daily X 10 days
Study: NCT02777112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-mental health program
Description: This program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-mental health program and job coaching
Description: This combines the e-mental health program and interactive job coaching delivered through telephone. The e-mental health program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking. The job coaching can be accessed by appointment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: Receiving generic information about men's depression from the Movember Foundation website: https://ca.movember.com/programs/mental-health
Study: NCT02815449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals prepared with iron fortified cube with Low stabilizer level
Description: Meals prepared with iron fortified cube with Low stabilizer level

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals prepared with iron fortified cube with Medium stabilizer level
Description: Meals prepared with iron fortified cube with Medium stabilizer level

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals prepared with iron fortified cube with High stabilizer level
Description: Meals prepared with iron fortified cube with High stabilizer level
Study: NCT01066091

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mashed potatoes
Description: Mashed potatoes: Potatoes + Skim milk powder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mashed potatoes + Oleic acid
Description: Mashed potatoes with 1g/Kg of weight, of lipids with 75% of Oleic Acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mashed potatoes + Palmitic acid
Description: Mashed potatoes with 1g/Kg of weight, of lipids with 32% of palmitic acid
Study: NCT03757975

Intervention type: PROCEDURE
Intervention: urethral length measure
Description: measure of urethral length, distribution of questionnaires before and after operation

Intervention type: PROCEDURE
Intervention: urethral length measure
Description: measure of urethral length, distribution of questionnaires before and after operation

Intervention type: PROCEDURE
Intervention: urethral length measure
Description: measure of urethral length, distribution of questionnaires before and after operation

Intervention type: PROCEDURE
Intervention: urethral length measure
Description: measure of urethral length, distribution of questionnaires before and after operation

Intervention type: PROCEDURE
Intervention: urethral length measure
Description: measure of urethral length, distribution of questionnaires before and after operation
Study: NCT03276065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser depilation
Description: Fitzpatrick skin type classification will be assessed during the initial visit. The Fitzpatrick skin type classification is based on the level of pigmentation of the skin and its response to ultraviolet light (See Appendix). It will be used to select the best laser to perform hair removal for each patient. The laser treatment group will consist of an 810 nm (for Fitzpatrick skin types I-IV) or Nd:YAG (for Fitzpatrick skin types V-VI) 28 joule application at auto pulse duration for 400 ms. A cooling platform and application of 7% lidocaine/ 7% tetracaine cream, applied 45 minutes prior to treatment, will minimize any discomfort associated with the heat of the laser treatments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care hair depilation
Description: Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
Study: NCT01190943

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02160275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas (Inreda Diabetic BV)
Description: Bi-hormonal reactive closed loop system without mealtime announcement, miniaturized prototype

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump therapy
Description: Patients' own insulin pump with fast-acting insulin analog